Lancet Rheumatology

Article	Citations
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study	756
Tocilizumab in patients with severe COVID-19: a retrospective cohort study	686
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia	550
Anakinra for severe forms of COVID-19: a cohort study	493
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study	228
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study	216
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study	208
COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study	196
Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome	190
Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine	186
The immunology of COVID-19: is immune modulation an option for treatment?	179
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study	171
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study	164
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial	148
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries	143
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	135
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial	133
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study	127
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study	127
Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout	123
COVID-19 vasculitis and novel vasculitis mimics	123
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies	118
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study	116
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis	116
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial	113

Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment	113
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study	106
COVACTA trial raises questions about tocilizumab's benefit in COVID-19	101
COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study	100
Canakinumab in a subgroup of patients with COVID-19	98
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study	95
Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases	94
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study	91
Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study	91
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative	90
Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?	80
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses	78
Preventing COVID-19-induced pneumonia with anticytokine therapy	76
Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study	74
Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study	72
Perspective of patients with autoimmune diseases on COVID-19 vaccination	72
Viral arthritis and COVID-19	71
Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study	70
Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021	69
Too long to wait: the impact of COVID-19 on elective surgery	65
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study	64
Flare of rheumatoid arthritis after COVID-19 vaccination	64
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform	63
Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study	62
First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection	61
B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?	60
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies	57
Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study	57
Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19	54
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study	54
Of mice and men: converging on a common molecular understanding of osteoarthritis	53
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial	53
Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis	52
Reactivation of IgA vasculitis after COVID-19 vaccination	51
Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach	51
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Ear	51
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial	51
68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study	50
COVID-19 and systemic lupus erythematosus: a case series	50
Adverse events after first COVID-19 vaccination in patients with autoimmune diseases	50
Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms	47
Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial	46
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platf	45
Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection	44
Adult-onset Still's disease after mRNA COVID-19 vaccine	43
Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis	42
Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population	41
Anakinra in COVID-19: important considerations for clinical trials	38
Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases	38
Adult-onset Still's disease following COVID-19 vaccination	37

Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study	37
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab	36
First manifestation of adult-onset Still's disease after COVID-19	36
COVID-19 cytokine storm: targeting the appropriate cytokine	35
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure	35
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial	35
Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study	35
Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial	35
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials	34
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort s	34
Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study	34
Hydroxychloroquine in the prevention of COVID-19 mortality	33
COVID-19 in children and young people	33
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial	33
The role of antirheumatics in patients with COVID-19	33
Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses	32
Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial	31
Arthritis after SARS-CoV-2 infection	31
Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study	31
Tocilizumab for severe COVID-19 pneumonia – Authors' reply	31
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a popul	30
COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study	30
Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study	30
Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study	30
Inflammatory myositis after ChAdOx1 vaccination	29
Cutaneous vasculitis following COVID-19 vaccination	29
COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey	28
The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus	28
The conundrum of interleukin-6 blockade in COVID-19	28
Caution and clarity required in the use of chloroquine for COVID-19	27
Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry	27
Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease	27
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2	27
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort stud	27
Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology	26
Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	26
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial	26
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica secondary to herniated lumbar disc (NERVES): a phase 3, multicentre, open-label, randomised controll	26
Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study	26
SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study	25
Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, rando	25
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial	25
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study	25
Divergent effects of acute versus chronic glucocorticoids in COVID-19	24
How long does a shoulder replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 10 years of follow-up	23
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study	23
Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients	23
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised,	23
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study	22
Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease	22
Serious postoperative complications and reoperation after carpal tunnel decompression surgery in England: a nationwide cohort analysis	22
Risk-based stratified primary care for common musculoskeletal pain presentations (STarT MSK): a cluster-randomised, controlled trial	22
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial	21
Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre	21
Investigating sex differences in T regulatory cells from cisgender and transgender healthy individuals and patients with autoimmune inflammatory disease: a cross-sectional study	21
Lessons for rituximab therapy in patients with rheumatoid arthritis	21
Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases	21
Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study	21
Non-steroidal anti-inflammatory drug use in COVID-19	20
Stratified care versus usual care for management of patients presenting with sciatica in primary care (SCOPiC): a randomised controlled trial	20
Type I interferon, anti-interferon antibodies, and COVID-19	20
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a p	20
Current issues in rheumatoid arthritis-associated interstitial lung disease	19
Moderators of the effect of therapeutic exercise for knee and hip osteoarthritis: a systematic review and individual participant data meta-analysis	19
5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial	19
Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective	19
Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials	18
How long do revised and multiply revised knee replacements last? A retrospective observational study of the National Joint Registry	18
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study	18
Detection of IgM and IgG antibodies against SARS-CoV-2 in patients with autoimmune diseases	18
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study	17
How long do revised and multiply revised hip replacements last? A retrospective observational study of the National Joint Registry	17
Therapeutic implications of ongoing alveolar viral replication in COVID-19	17
Remotely delivered cognitive behavioural and personalised exercise interventions for fatigue severity and impact in inflammatory rheumatic diseases (LIFT): a multicentre, randomised, controlled, open-	17
The STAR care pathway for patients with pain at 3 months after total knee replacement: a multicentre, pragmatic, randomised, controlled trial	17
Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort	17
Incident systemic rheumatic disease following COVID-19	17
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial	17
Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study	17
The global epidemic of low back pain	16

Clinical and molecular associations with outcomes at 2 years after acute knee injury: a longitudinal study in the Knee Injury Cohort at the Kennedy (KICK)	16
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study	16
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised contr	16
Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab	15
MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study	15
Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage	15
Utility of repeated antinuclear antibody tests: a retrospective database study	15
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-contro	15
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial	15
Iloprost for COVID-19-related vasculopathy	15
Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study	15
Diagnostic accuracy of vascular ultrasound in patients with suspected giant cell arteritis (EUREKA): a prospective, multicentre, non-interventional, cohort study	15
Patients with gout: an under-recognised group at high risk of COVID-19	15
IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19	14
Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10-year retrospective review of medical records	14
Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study	14
Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study	14
Rheumatologists rapidly adjust patient care during COVID-19 pandemic	14
Making a big impact with small datasets using machine-learning approaches	14
Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study	14
Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases	14
Systemic sclerosis in the time of COVID-19	14
Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/	14
Delving beneath the surface of hyperinflammation in COVID-19	14
An adult presentation consistent with PIMS-TS	14
Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis	13
FDA approval for anifrolumab in patients with lupus	13
Anakinra for severe forms of COVID-19	13
Clinician-reported outcome measures in lupus trials: a problem worth solving	13
High-stakes heterogeneity in COVID-19	13
Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial	12
SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period	12
Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19	12
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled sub	12
Rapid distribution of information by SMS-embedded video link to patients during a pandemic	12
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	12
Global, regional, and national burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	12
Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study	12
Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies	12
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study	11
Coronavirus is the trigger, but the immune response is deadly	11
The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLH	11
Tolerance-inducing medicines in autoimmunity: rheumatology and beyond	11
Prediction models for the risk of total knee replacement: development and validation using data from multicentre cohort studies	11
Immunosuppression and SARS-CoV-2 breakthrough infections	11
Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study	11
COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases	11
Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination	11
The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis	11
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	11
Referring early arthritis patients within 6 weeks versus 12 weeks after symptom onset: an observational cohort study	10
Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma	10
Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial	10
Changing COVID-19 outcomes in patients with rheumatic disease—are we really getting better at this?	10
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries	10
Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis	9
The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study	9
Mental health before and during the pandemic in people with systemic sclerosis	9
Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases	9
The opening salvo of anti-complement therapy against COVID-19	9
Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe?	9
Monkeypox associated acute arthritis	9
Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases	9
Gender representation on editorial boards of rheumatology journals	9
Pulmonary intravascular coagulopathy in COVID-19 pneumonia – Authors' reply	9
Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study	9
Bilateral anterior non-necrotising scleritis, anterior uveitis, and unilateral facial nerve palsy in paediatric inflammatory multisystem syndrome temporally associated with COVID-19	9
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial	9
The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease	9
Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre,	9
Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level	9
Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomis	9
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study	9
Autoantigens in rheumatoid arthritis and the potential for antigen-specific tolerising immunotherapy	9
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	9
Digital ulcers: should debridement be a standard of care in systemic sclerosis?	9
Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City	9